Literature DB >> 17502046

Outcome measures in systemic sclerosis: an update on instruments and current research.

Dinesh Khanna1, Peter A Merkel.   

Abstract

Substantial progress has been made in the past 10 years in the development and validation of outcome measures and refinement of trial methodology for systemic sclerosis (scleroderma, SSc). These advances in outcome measures have focused mostly on specific organ systems involved in SSc. Many of these new tools have been validated and subsequently adapted for use in multicenter clinical trials. Newer outcome measures in development are intended to more precisely quantify clinically meaningful change in specific organ systems, and some methods aim to assess overall disease burden in SSc. This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development.

Entities:  

Mesh:

Year:  2007        PMID: 17502046     DOI: 10.1007/s11926-007-0010-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  51 in total

1.  Scleroderma--developing measures of response.

Authors:  Daniel E Furst; Dinesh Khanna; Marco Mattucci-Cerinic; Alan J Silman; Peter A Merkel; Ivan Foeldvari
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

Review 2.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

3.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

4.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

5.  Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  T Y Martinez; C A Pereira; M L dos Santos; R M Ciconelli; S M Guimarães; J A Martinez
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

6.  Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument.

Authors:  A Silman; A Akesson; J Newman; H Henriksson; G Sandquist; M Nihill; S Palfrey; R Lomas; F Wollheim; C Black
Journal:  J Rheumatol       Date:  1998-01       Impact factor: 4.666

7.  Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis.

Authors:  S J Wang; J L La; D Y Chen; Y H Chen; T Y Hsieh; W Y Lin
Journal:  Clin Rheumatol       Date:  2002-02       Impact factor: 2.980

8.  Health values of patients with systemic sclerosis.

Authors:  Dinesh Khanna; Mansoor Ahmed; Daniel E Furst; Shaari S Ginsburg; Grace S Park; Richard Hornung; Joel Tsevat
Journal:  Arthritis Rheum       Date:  2007-02-15

9.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

10.  Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.

Authors:  Maureen D Mayes; Daniel O'Donnell; Naomi F Rothfield; M E Csuka
Journal:  Arthritis Rheum       Date:  2004-02
View more
  30 in total

Review 1.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

2.  Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Authors:  P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold
Journal:  Arthritis Rheum       Date:  2012-10

3.  Development of a provisional core set of response measures for clinical trials of systemic sclerosis.

Authors:  D Khanna; D J Lovell; E Giannini; P J Clements; P A Merkel; J R Seibold; M Matucci-Cerinic; C P Denton; M D Mayes; V D Steen; J Varga; D E Furst
Journal:  Ann Rheum Dis       Date:  2007-09-24       Impact factor: 19.103

4.  The correlation between durometer score and modified Rodnan skin score in systemic sclerosis.

Authors:  Ki Won Moon; Ran Song; Jin Hyun Kim; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2011-07-19       Impact factor: 2.631

5.  Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Authors:  Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

Review 6.  Old medications and new targeted therapies in systemic sclerosis.

Authors:  Vivek Nagaraja; Christopher P Denton; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2014-07-26       Impact factor: 7.580

Review 7.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

8.  Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?

Authors:  Adam J N Raymakers; Nicole W Tsao; Carlo A Marra; Philip J Clements; Dinesh Khanna
Journal:  J Rheumatol       Date:  2016-08-01       Impact factor: 4.666

9.  Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.

Authors:  Marian Kaldas; Puja P Khanna; Daniel E Furst; Philip J Clements; Weng Kee Wong; James R Seibold; Arnold E Postlethwaite; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2009-07-14       Impact factor: 7.580

10.  A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index.

Authors:  D Khanna
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.